重组杆状病毒细小VP2蛋白40L生物反应器放大工艺研究
|
摘要
研究了Sf9细胞生产重组杆状病毒细小VP2蛋白在机械搅拌式生物反应器(STR)中从3L至40L的放大工艺。首先在3L反应器中,通过DO和搅拌转速的优化,使反应器中的VP2蛋白HA效价不低于摇瓶结果。在40L反应器放大时,温度、p H、DO保持不变,根据输入搅拌功率、体积溶氧系数和叶尖线速度等工程参数的计算,得到了该反应器的合理搅拌转速,最终HA效价测定结果与小罐一致。豚鼠免疫试验证实,反应器中表达的VP2蛋白制成疫苗,与HN2011灭活苗及商品化灭活疫苗相比,抗体水平上升较快且高于传统灭活苗。
The focuses are on the scale-up of a Sf9 cell line to produce recombinant porcine parvovirus( PPV) VP2 protein expression using baculovirus/insect expression system from the initial 3-L bench scale to the40-L scale. In 3 L bioreactor,HA titer of VP2 protein side-by-side comparison of shake flask by optimization of DO and Agit. The operational parameters of temperature,DO,and p H for large vessels were set at the same values as those of 3-L bioreactor. Appropriately applying the calculated results to power input per volume,oxygen transfer coefficient and tip speed,resulted in successful scale-up of agitation speed for the large bioreactors. By HA titer analysis,VP2 protein had identical haemagglutinating activity comparison of 3-L. By guinea pig immunization test,It is found that recombinant VP2 subunit vaccine can be induced high level antibody reaction,and immune with recombinant VP2 subunit vaccine was faster than classical inactivated PPV vaccine.
The focuses are on the scale-up of a Sf9 cell line to produce recombinant porcine parvovirus( PPV) VP2 protein expression using baculovirus/insect expression system from the initial 3-L bench scale to the40-L scale. In 3 L bioreactor,HA titer of VP2 protein side-by-side comparison of shake flask by optimization of DO and Agit. The operational parameters of temperature,DO,and p H for large vessels were set at the same values as those of 3-L bioreactor. Appropriately applying the calculated results to power input per volume,oxygen transfer coefficient and tip speed,resulted in successful scale-up of agitation speed for the large bioreactors. By HA titer analysis,VP2 protein had identical haemagglutinating activity comparison of 3-L. By guinea pig immunization test,It is found that recombinant VP2 subunit vaccine can be induced high level antibody reaction,and immune with recombinant VP2 subunit vaccine was faster than classical inactivated PPV vaccine.
引文
[1]杜毅超,吴健敏,刘金凤.猪细小病毒病毒样颗粒研究进展.动物医学进展,2016,37(7):71-75.Du Y C,Wu J M,Liu J F.Progress on porcine parvovirus viruslike particles.Progress in Veterinary Medicine,2016,37(7):71-75.
[2]Lager K M,Mengeling W L.Porcine parvovirus associated with cutaneous lesions in piglets.J Vet Diagn Invest,1994,6(3):357-359.
[3]Bolt D M,Waldvogel A S,Hni H,et al.Non-suppurative myocarditis in piglets associated with porcine parvovirus infection.J Comp Pathol,1997,117(2):107-118.
[4]Kushnir N,Streatfield S J,Yusibov V.Virus-like particles as a highly efficient vaccine platform:Diver-sity of targets and production systems and advances in clinical development.Vaccine,2012,31(1):58-83.
[5]苌生科.PPV/HN-2011毒株分子生物学特性研究及利用杆状病毒表达其VP2蛋白.郑州:河南农业大学,2013.Chang S K.Porcine parvovirus HN-2011 molecular biological characteristics and expressed VP2 protein in insect baculovirus cell system.Zhengzhou:Henan Agricultural University,2013.
[6]Martine Z C,Dalsgaard K,Lopezde Turiso J A,et al.Production of porcine parvovirus empty capsids with high immunogenic activity.Vaccine,1992,10(10):684-690.
[7]Adriaan F G,Christianne J M,Palomar,et al.A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.Vaccine,2006,24:5481-5490.
[8]Yang J D,Lu C,Stasny B,et al.Fed-batch bioreactor process scale-up from 3-L to 2 500-L scale for monoclonal antibody production from cell culture.Biotechnology and Bioengineering,2007,98(1):141-154.
[9]Dreher T,Husemann U,Adams T,et al.Design space definition for a stirred single-use bioreactor family from 50 to 2000L scale.Eng Life Sci,2014,14:304-310.
[10]Agathos S N.Insect cell bioreactors.Cytotechnology,1996,20:173-189.
[2]Lager K M,Mengeling W L.Porcine parvovirus associated with cutaneous lesions in piglets.J Vet Diagn Invest,1994,6(3):357-359.
[3]Bolt D M,Waldvogel A S,Hni H,et al.Non-suppurative myocarditis in piglets associated with porcine parvovirus infection.J Comp Pathol,1997,117(2):107-118.
[4]Kushnir N,Streatfield S J,Yusibov V.Virus-like particles as a highly efficient vaccine platform:Diver-sity of targets and production systems and advances in clinical development.Vaccine,2012,31(1):58-83.
[5]苌生科.PPV/HN-2011毒株分子生物学特性研究及利用杆状病毒表达其VP2蛋白.郑州:河南农业大学,2013.Chang S K.Porcine parvovirus HN-2011 molecular biological characteristics and expressed VP2 protein in insect baculovirus cell system.Zhengzhou:Henan Agricultural University,2013.
[6]Martine Z C,Dalsgaard K,Lopezde Turiso J A,et al.Production of porcine parvovirus empty capsids with high immunogenic activity.Vaccine,1992,10(10):684-690.
[7]Adriaan F G,Christianne J M,Palomar,et al.A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.Vaccine,2006,24:5481-5490.
[8]Yang J D,Lu C,Stasny B,et al.Fed-batch bioreactor process scale-up from 3-L to 2 500-L scale for monoclonal antibody production from cell culture.Biotechnology and Bioengineering,2007,98(1):141-154.
[9]Dreher T,Husemann U,Adams T,et al.Design space definition for a stirred single-use bioreactor family from 50 to 2000L scale.Eng Life Sci,2014,14:304-310.
[10]Agathos S N.Insect cell bioreactors.Cytotechnology,1996,20:173-189.